Protection from Experimental Cerebral Malaria with a Single Dose of Radiation-Attenuated, Blood-Stage Plasmodium berghei Parasites by Gerald, Noel J. et al.
Protection from Experimental Cerebral Malaria with a
Single Dose of Radiation-Attenuated, Blood-Stage
Plasmodium berghei Parasites
Noel J. Gerald, Victoria Majam, Babita Mahajan, Yukiko Kozakai, Sanjai Kumar*
Division of Emerging Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, United States of
America
Abstract
Background: Whole malaria parasites are highly effective in inducing immunity against malaria. Due to the limited success
of subunit based vaccines in clinical studies, there has been a renewed interest in whole parasite-based malaria vaccines.
Apart from attenuated sporozoites, there have also been efforts to use live asexual stage parasites as vaccine immunogens.
Methodology and Results: We used radiation exposure to attenuate the highly virulent asexual blood stages of the murine
malaria parasite P. berghei to a non-replicable, avirulent form. We tested the ability of the attenuated blood stage parasites
to induce immunity to parasitemia and the symptoms of severe malaria disease. Depending on the mouse genetic
background, a single high dose immunization without adjuvant protected mice from parasitemia and severe disease (CD1
mice) or from experimental cerebral malaria (ECM) (C57BL/6 mice). A low dose immunization did not protect against
parasitemia or severe disease in either model after one or two immunizations. The protection from ECM was associated with
a parasite specific antibody response and also with a lower level of splenic parasite-specific IFN-c production, which is a
mediator of ECM pathology in C57BL/6 mice. Surprisingly, there was no difference in the sequestration of CD8+ T cells and
CD45+ CD11b+ macrophages in the brains of immunized, ECM-protected mice.
Conclusions: This report further demonstrates the effectiveness of a whole parasite blood-stage vaccine in inducing
immunity to malaria and explicitly demonstrates its effectiveness against ECM, the most pathogenic consequence of malaria
infection. This experimental model will be important to explore the formulation of whole parasite blood-stage vaccines
against malaria and to investigate the immune mechanisms that mediate protection against parasitemia and cerebral
malaria.
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Introduction
Studies of natural immunity to human malaria and evidence
from experimental models suggest that repeated exposure to
malaria parasites is the most effective method to induce immunity
against malaria [1]. Likewise, the most successful experimental
malaria vaccine is based on repeated immunizations with
radiation-attenuated malaria sporozoites delivered by multiple
bites from infected mosquitoes [2]. In Plasmodium falciparum
malaria, the immunity induced by irradiated sporozoites is
species-dependent yet it is cross-protective against different
parasite strains [3]. Attenuated parasite vaccines have long been
an interest for malaria [1], and so far the major efforts to develop
such whole organism vaccines have focused on generating
attenuated sporozoites by radiation [4,5], chemical [6], drug cure
[7], or targeted gene disruption methods [8,9,10]. In comparison,
less research has been done on live vaccines against the malaria
blood stages which are responsible for the clinical symptoms of the
disease [1,11]. However, attenuated blood-stage vaccines pro-
duced by radiation [12,13] gene disruption [14,15,16], and drug
cure methods [17,18], have demonstrated effectiveness for
protection against parasitemia and symptoms of severe malaria.
In the current study, we investigate the effectiveness of a
radiation-attenuated blood-stage parasites for protection against
parasitemia and severe disease in experimental models of malaria.
We used the highly virulent murine malaria parasite Plasmodium
berghei ANKA (Pb-A) which, depending on the mouse genetic
background, produces two distinct yet uniformly fatal pathologies.
In CD1 mice, a few virulent blood-stage Pb-A are sufficient to
initiate a patent infection that ultimately produces high parasite
parasitemia, severe anemia, and death. In contrast, C57BL/6
mice infected with Pb-A are susceptible to experimental cerebral
malaria (ECM) which is characterized by an early onset of
neurological defects, coma, and death associated with a relatively
low parasitemia [19,20]. We show that a single, non-adjuvanted
immunization with a high-dose of radiation-attenuated, blood-
stage Pb-A parasites protected CD1 mice from parasitemia and
severe disease, and it protected C57BL/6 mice from ECM.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24398Protection from ECM was associated with an anti-parasite
antibody response and a reduced IFN-c response in the spleen
during a virulent infection.
Materials and Methods
Mice, parasites, and immunizations
Ethics statement. 6–8 week old female C57BL/6 and Swiss-
CD1 mice were used in accordance with the animal study
protocols (#2009-22, 2007-14) approved by the Food and Drug
Administration, Center for Biologics Evaluation and Research
Institutional Animal Care and Use Committee. Blood-stage
Plasmodium berghei ANKA (Pb-A) parasites (an uncloned parasite
line) from 270 C glycerolyte stocks were injected intraperitoneally
into donor mice with the same genetic background of the
experimental mice [19]. Parasitemia was monitored by Giemsa-
stained thin blood smears and total RBC were counted by
hemocytometer. For challenge infections, 10
4 parasitized RBC
(pRBC) were injected intravenously (iv) via the tail vein. Mice were
evaluated for ECM symptoms and the ability to survive beyond
day 10 post infection as previously described [20]. For
immunization, 10
3 or 10
7 irradiated pRBC were injected into
mice iv as described in the text.
Radiation-attenuation of parasite growth
To attenuate parasite growth, freshly harvested Pb-A pRBC
were diluted in phosphate buffered saline (PBS) to a concentration
of 5610
7 pRBC per milliliter (ml). One ml aliquots of parasites
were then immediately exposed to a Cesium-137 source for
various time periods at room temperature in a Gammacell 1000
irradiator. Radiation dose was calculated from the machine-
specific estimate of 1505 Rads per minute.
Spleen cell culture
Culture media and buffers were obtained from Invitrogen unless
specified otherwise. Freshly isolated mouse splenocytes were plated
in triplicate in 24-well tissue culture plates. For parasite antigen
stimulation, pRBC were lysed with 4 freeze/thaw cycles, and
1610
6 pRBC equivalents were added per well. Control wells were
stimulated with an equal number of lysed uninfected RBC, or with
medium alone. Cells were cultured for 72 hours, then superna-
tants were collected by centrifugation and stored at 270 C.
Interferon-gamma protein levels were assayed in culture superna-
tants using the Ready-Set-Go sandwich ELISA kit (Ebioscience)
according to the manufacturer’s instructions with a stated
detection sensitivity limit of 15 pg/ml.
Brain sequestered cells
Brain cell suspensions were prepared as described [21]. Briefly,
the brains of anesthetized mice were perfused intracardially with
Hank’s Buffered Saline Solution (HBSS), removed, and then
pushed through 70 micron filters. Cell suspensions were
centrifuged at 4006g at 21 C, and the pellets were resuspended
in RPMI/FCS with 0.5 mg/ml collagenase D (Roche), 3 units/ml
DNAse (Roche), and 5 mM MgCl2. The samples were rotated for
60 minutes at room temperature, allowed to stand for 10–
15 minutes, and the supernatants were collected. Each sample
was brought to a final concentration 33% Percoll (Sigma-Aldrich)
and then under-layered with 70% Percoll/HBSS. The gradients
were centrifuged at 5156g for 30 minutes at 21 C, the cells were
collected from the 33/70% interface, and washed with HBSS.
Residual red blood cells were lysed with ACK lysis buffer, and the
samples were washed twice in RPMI/FCS before preparation for
multicolor flow cytometry.
Flow Cytometry
Brain cells (pooled from 4 mice within each group) were stained
with the Fixable Viability Dye eFluor 660 (eBioscience) according
to the manufacturer’s instructions. Cells were blocked with
TruStain fcX anti-mouse CD16/32 (Biolegend) and then stained
in HBSS, 1% BSA on ice for 30 minutes with the following anti-
mouse antibodies: AlexaFluor 488-CD8a (Biolegend), PE-NK1.1
(Biolegend), PerCP-CD11b (Biolegend), APC-eFluor 780-CD45
(eBioscience), eFluor 450-CD3, AlexaFluor488-CD44 (Biolegend),
PE-CD62L (Biolegend), PerCP-CD69 (Biolegend), APC-eFluor
780-CD8a (eBioscience), and then fixed with IC fixation buffer
(eBioscience). Samples were read on an LSRII cytometer (BD).
Fluorescence-minus-one (FMO) controls were used to set popu-
lation gates for each panel. Data analysis was performed in FlowJo
v7.5 software. 36,000–160,000 cells were analyzed for each pooled
brain sample.
Serum antibody ELISA
Mouse sera were pooled within treatment groups and then
stored at 220 C. Pb-A-specific antibodies were detected by
endpoint ELISA at O.D. 405 nm as previously described [22].
Positive signal cut-off was defined as two times the mean O.D.
value from normal sera. Antibody titer was determined as the
highest sample dilution which produced an O.D. value greater
than or equal to the cut-off.
Statistics
Graphs, survival analysis, and statistics were performed in
GraphPad Prism 5 (Graphpad Software, Inc). Two-sided p-values
and 95% confidence intervals are reported. Survival to day 10 in
ECM experiments was analyzed using Fisher’s exact test as
previously described [20]. For Two-Way ANOVA, the Bonferroni
correction for multiple comparisons on post tests was used.
Results
Determination of the radiation dose necessary to
attenuate blood-stage Pb-A
To determine the radiation dose necessary to attenuate Pb-A
growth and virulence, parasitized red blood cells (pRBC) were
exposed to increasing doses of radiation. Parasite attenuation was
evaluated by intravenously (iv) injecting 10
7 irradiated pRBC into
CD1 mice and then monitoring the mice for parasite growth and
disease symptoms (Figure 1). Parasites irradiated at doses up to
60 kilorads reproduced in the mice, and these mice developed
patent parasitemias within 7 days (Figure 1, Ctrl, 10–60 krad
groups). Higher radiation doses produced greater evidence of
parasite attenuation. All of the mice that received 80 kilorad
irradiated parasites (14/14) were free of patent infection through
day 7, and 70% (10/14) did not develop detectable parasitemias or
disease symptoms for the duration of the experiment (Figure 1,
open circles). However, by day 14, 30% (4/14) of the mice that
had been injected with 80 kilorad irradiated parasites developed
patent infections and severe disease symptoms. This suggested that
the 80 kilorad irradiation attenuated the growth and virulence of
the majority of the parasites, but that a few residual parasites
escaped attenuation and were eventually able to establish
fulminant infections.
In contrast, all of the mice (10/10) that received 100 kilorad
irradiated parasites (Figure 1, open squares, solid line) remained
free from patent parasitemia and disease symptoms for the
duration of the experiment. This demonstrated that the 100 ki-
lorad dose was sufficient to cause the complete attenuation of
Immunity Induced by Irradiated BS Pb-A
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to attenuate parasite growth in subsequent experiments.
Attenuated Pb-A blood-stage parasites induce protection
against parasitemia and severe disease in CD1 mice
We determined whether iv immunization with 10
3 or 10
7
irradiated Pb-A blood-stage parasites (IrrPb) protected CD1 mice
against parasitemia and/or severe disease after a challenge
infection with virulent blood-stage Pb-A (Figure 2A). No residual
IrrPb were detected in the blood smears of immunized mice on the
day before the virulent challenge. After challenge, the group
immunized with 10
3 IrrPb displayed an uncontrolled blood
infection similar to naı ¨ve mice, and none of these mice (0/5)
survived beyond day 12 without developing severe disease
symptoms. In contrast, the group immunized with 10
7 IrrPb
(n=5, Figure 2A, open squares) showed evidence of controlling
the blood stage infection after challenge, and reached a peak mean
parasitemia of 7.3% on day 8 with only one of these mice
developing severe disease symptoms on this day. 80% (4/5) of the
10
7 IrrPb immunized mice did not develop severe malaria
symptoms and their mean parasitemias decreased to low or
undetectable levels by day 21 (Figure 2A). These mice remained
free from disease symptoms for 5 months of observation after
challenge. This is strong evidence that a single immunization with
10
7 IrrPb protects CD1 mice from virulent challenge, while a
similar immunization with 10
3 IrrPb is not protective.
To test whether more than one immunization of attenuated
parasites would improve protection, groups of CD1 mice were
immunized with 10
3 or 10
7 IrrPb and 24 days later they were
given a booster immunization with an equal number of IrrPb. The
mice were then challenged with virulent Pb-A pRBC and
parasitemia was monitored (Figure 2B). Similar to naı ¨ve mice
(Figure 2B, filled circles), mice immunized twice with 10
3 IrrPb
(Figure 2B, open triangles) displayed continually increasing
parasite growth after challenge. Mice that had received two
immunizations with 10
7 IrrPb (n=5, Figure 2B, open squares)
developed a peak mean parasitemia of 9.7% on day 8 after
challenge, and by day 21, all of these mice (5/5) had controlled
parasitemias down to low or undetectable levels. Similar to the
results from single immunization experiments (Figure 2A), these
results demonstrated that two immunizations with 10
7 IrrPb was
protective in a model of acute blood-stage disease, while two
immunizations with 10
3 IrrPb was not protective.
Attenuated Pb-A blood-stage parasites induce protection
against ECM in C57BL/6 mice
Since immunization with IrrPb protected CD1 mice from
parasitemia and acute blood-stage disease, we wanted to test
Figure 1. Determination of the radiation dose necessary to
attenuate blood-stage Pb-A parasites. Virulent Pb-A parasitized
RBC (pRBC) were exposed to increasing doses of gamma irradiation (10,
20, 40, 60, 80, 100 kilorads). 10
7 irradiated pRBC or non-irradiated
control pRBC (Ctrl) were injected intravenously (iv) into groups of naı ¨ve
CD1 mice and parasitemia was monitored by blood smear. The graph
shows the percentage of mice without patent parasitemia in each
group over time beginning with day 2. Data are pooled from 3
experiments. Groups of mice infected with control pRBC or with pRBC
exposed to 10, 20, 40, or 60 krad irradiation all developed patent
parasitemia by day 7 (n=4 mice each group). Accordingly, the curves
describing these groups approach 0% by day 7. 70% (10/14) of mice
infected with 80 krad irradiated pRBC remained free from patent blood-
stage disease by day 14 (open circles, dashed line). 100% (10/10) of the
mice injected with 100 krad irradiated pRBC remained free from blood
stage infection under the period of observation (open squares, solid
line). 100 krad irradiation was chosen as the attenuating dose in
subsequent experiments.
doi:10.1371/journal.pone.0024398.g001
Figure 2. Protection from parasitemia and severe disease in
CD1 mice after immunization with irradiated blood-stage Pb-A.
A) Protection in CD1 mice after a single immunization with 10
7
irradiation attenuated Pb-A blood-stage parasites (IrrPb). 10
3 or 10
7
IrrPb were injected iv into groups mice. On day 24 after injection,
immunized and naı ¨ve mice were challenged with 10
4 virulent Pb-A
pRBC and parasitemia was monitored by blood smear (mean +/2 SD)
Daggers indicate mice that were euthanized or that died during the
experiment. All naı ¨ve mice (4/4, filled circles) and 10
3 IrrPb immunized
mice (5/5, open triangles) displayed uncontrolled parasite growth and
succumbed to acute blood-stage infection by day 12 after challenge. In
contrast, mice immunized with 10
7 IrrPb (4/5, open squares) controlled
parasite growth after challenge and managed blood parasitemia down
to low or undetectable levels. B) Protection in CD1 mice after a two
immunizations with 10
7 IrrPb. Groups of mice were immunized with 10
3
or 10
7 IrrPb, and then given a boost immunization 24 days later with an
equal number of IrrPb (Boost). 24 days after the final immunization,
immunized and naı ¨ve mice were challenged with 10
4 virulent Pb-A
pRBC. In mice immunized with 2 doses of 10
3 IrrPb (n=5 mice, open
triangles), parasitemia levels continued to increase after challenge,
similar to naı ¨ve mice (n=5 mice, filled circles). In contrast, when mice
were immunized with 2 doses of 10
7 IrrPb (n=5 mice, open squares),
blood parasitemia declined over time to low or undetectable levels.
doi:10.1371/journal.pone.0024398.g002
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C57BL/6 mice from the symptoms of experimental cerebral
malaria (ECM). Groups of C57BL/6 mice immunized once
with 10
3 or 10
7 IrrPb were challenged with virulent Pb-A pRBC
and then monitored for the symptoms of ECM, survival beyond
day 10, and blood parasitemia (Figures 3A and 3B). After
challenge, 10% (1/10) of naı ¨ve mice (filled circles) and 12% (2/
17) of mice immunized with 10
3 IrrPb (open triangles) survived
beyond day 10 (Figure 3A). The mean parasitemia levels were
below 10% for all groups before day 10 (Figure 3B). This is
consistent with the ECM model in C57BL/6 mice, and
suggested that immunization with 10
3 IrrPb did not offer any
significant protection from ECM or parasitemia. In contrast,
81% (17/21) of mice immunized with 10
7 IrrPb (open squares)
did not display any symptoms of ECM and survived beyond
day 10 (Figure 3A, p=.0003 survival to day 10, naı ¨ve vs. 10
7
IrrPb immunized mice). This is very strong evidence that a
single immunization with 10
7 IrrPb induced a high level of
protection from ECM. Similar to other reports in this model
[23], the mice that were protected from ECM and survived
beyond day 10 still succumbed to hyperparasitemia by the end
of the experiment (Figure 3B).
To test whether two immunizations with IrrPb enhanced
protection from ECM, C57BL/6 mice immunized twice with 10
3
or 10
7 IrrPb with a 28 day interval were challenged with virulent
Pb-A pRBC (Figures 3C and 3D). After challenge, 20% (1/5) of
naı ¨ve mice (filled circles) and none (0/10) of the mice immunized
twice with 10
3 IrrPb (open triangles) survived to day 10, indicating
that two immunizations did not improve the ability of 10
3 IrrPb to
induce protection against ECM in this model. In contrast, 100%
(10/10) of the mice immunized twice with 10
7 IrrPb (open squares)
survived to day 10 after challenge (p=.0037, survival to day 10,
naı ¨ve vs. 10
7 IrrPb boost immunized mice), which was strong
evidence that two immunizations with 10
7 IrrPb protected from
ECM. Immunization with 10
7 IrrPb did not protect against
parasitemia in the C57BL/6 model since all mice that survived
ECM eventually succumbed to high parasite levels (Figure 3B and
D).
Protective immune responses associated with attenuated
Pb-A blood-stage parasites
We next investigated the antibody and cellular responses
induced by a single immunization with 10
3 or 10
7 IrrPb for
correlations with the protection from ECM. Pb-A-specific IgG
Figure 3. Protection from experimental cerebral malaria (ECM) in C57BL/6 mice after immunization with IrrPb. A and B) Protection
from ECM after a single immunization of 10
7 IrrPb. Data are pooled from two independent experiments. Groups of mice were immunized with 10
3 or
10
7 IrrPb and then challenged with 10
4 virulent Pb-A pRBC on day 19 or 28 after immunization. To assess ECM, challenged mice were monitored for
neurological symptoms, the ability to survive beyond day 10 (A), and blood parasitemia levels (B). A) 10% (1/10) of naı ¨ve mice (filled circles) and 12%
(2/17) of mice immunized with 10
3 IrrPb (open triangles) survived beyond day 10 after challenge. In contrast, 81% (17/21) of mice immunized with
10
7 IrrPb (open squares) survived beyond day 10 (two-sided p=.0003, 10
7 IrrPb group vs. naı ¨ve group, Fisher’s exact test). B) In each group, mice that
succumbed to ECM before day 10 had blood parasitemias less than 10%, while mice that survived beyond day 10 eventually developed
hyperparasitemia. C and D) Protection from ECM after two immunizations with 10
7 IrrPb. Mice were immunized with 10
3 or 10
7 IrrPb twice with a 28
day interval (Boost), challenged with 10
4 virulent pRBC, and then monitored for survival (C) and blood parasitemia (D). C) 20% (1/5) of naı ¨ve mice
(filled circles) and none (0/10) of the mice immunized twice with 10
3 attenuated parasites (open triangles) survived beyond day 10 after challenge. In
contrast, all (10/10) of the mice immunized with 10
7 attenuated parasites (open squares) survived beyond day 10 (p=.0037, 10
7 IrrPb group vs. naı ¨ve
group, Fisher’s exact test), and eventually developed hyperparasitemia (D).
doi:10.1371/journal.pone.0024398.g003
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3 IrrPb immunized
mice with or without challenge, similar to naı ¨ve mice (Figure 4A
and B). In contrast, Pb-A-specific IgG antibodies were detected in
sera from 10
7 IrrPb immunized mice before challenge (Figure 4A),
and antibody titers were detected at levels 1–2 log-fold higher in
the sera from these mice during a virulent challenge (Figure 4B).
Thus, the immunization with 10
7 IrrPb which was protective
against ECM generated a parasite-specific serum antibody
response, while the non-protective immunization with 10
3 IrrPb
did not produce a measureable antibody response.
Parasite-specific IFN-c responses were also measured in spleen
cell cultures from immunized mice before or during a virulent
infection (Figure 4C and 4D). Among uninfected mice, IFN-c was
not detected in samples from naı ¨ve or 10
3 IrrPb immunized mice
(Figure 4C, n.d). However, samples from uninfected 10
7 IrrPb
immunized mice did produce IFN-c protein in response to Pb
antigen stimulation (Figure 4C, black bar, PbAg), indicating that
immunization with only the higher dose of IrrPb was able to
induce IFN-c production by spleen cells in the absence of a
virulent infection.
During a virulent Pb-A challenge infection, the spleen cells from
naı ¨ve mice and 10
3 IrrPb immunized mice produced the highest
levels of IFN-c (Figure 4D). As described in Figure 3, these groups
had the highest prevalence of ECM, and this pattern of IFN-c
expression is consistent with published reports. In contrast, during
a virulent infection the spleen cells from the 10
7 IrrPb immunized
mice produced significantly less IFN-c in comparison with cells
from naı ¨ve mice, whether they were stimulated in vitro with
parasite antigen (Figure 4D, black bars. p,.0001, naı ¨ve vs. 10
7
IrrPb, mean difference 596 (411, 781) pg/ml) or unstimulated
(Figure 4D, white bars. p,.0001, naı ¨ve vs. 10
7 IrrPb, mean
difference 534 (349, 719) pg/ml).
Since a single immunization with 10
7 IrrPb 1) protected mice
from ECM, 2) produced a parasite-specific antibody response, and
3) was associated with a decreased IFN-c response in the spleen
during infection, we decided to examine the response to this
immunization further. Consistent with other studies using
attenuated blood-stage Pb-A, the average spleen weights from
immunized challenged mice (Figure 5, 10
7 IrrPb Challenged) were
1.5–2-fold larger than the spleen weights from naı ¨ve challenged
mice (p,.001, mean difference=0.17 (0.09, 0.24) grams),
suggesting an increased splenic activity during infection. In the
absence of a virulent Pb-A challenge, the spleens from immunized
mice were not significantly heavier than the spleens from naı ¨ve
mice (Figure 5, Unchallenged).
We next examined the immune cell subtypes in the brains of
mice after a single immunization with 10
7 IrrPb for correlations
with the protection from ECM (Figure 6). As reported previously,
Figure 4. Immune responses associated with IrrPb immunization in C57BL/6 mice. C57BL/6 mice were immunized once with 10
3 or 10
7
IrrPb, challenged with virulent pRBC, and tissues were harvested on day 6 when ECM appeared in naı ¨ve mice. A and B) Serum IgG antibodies
(subclasses IgG1, IgG2a, IgG2b, and IgG3) to blood-stage Pb-A antigen were measured by endpoint ELISA. Values are averaged from two independent
experiments. Parasite-specific IgG antibodies were not detected (n.d.) in sera from naı ¨ve mice or 10
3 IrrPb immunized mice before (A) or after
challenge (B) with virulent pRBC. Parasite-specific IgG antibodies were detected in sera from 10
7 IrrPb immunized mice before challenge (A), and the
antibody titers increased between 1 to 2 log-fold in the sera of these mice after challenge (B). C and D) Cellular responses: IFN-c responses in the
spleen during a virulent infection are reduced in immunized mice. Spleen cells from unchallenged (C) or challenged (D) mice were cultured with
blood-stage Pb-A antigen (Pb Ag), uninfected RBC (RBC), or media control (Unstim). IFN-c protein was measured in cell culture supernatants by
sandwich ELISA (mean +/2 SEM) C) Among unchallenged mice, IFN-c was not detected (n.d.) in samples from naı ¨ve mice or 10
3 IrrPb immunized
mice. A low level of IFN-c was detected in samples from 10
7 IrrPb immunized mice after stimulation with parasite antigen (Pb Ag, black bar). D)
During a virulent infection, the highest levels of IFN-c were detected in samples from naı ¨ve and 10
3 IrrPb immunized mice. 10
7 IrrPb immunized mice
had lower levels of antigen-stimulated IFN-c in comparison to antigen-stimulated samples from naı ¨ve mice (black bars, mean difference 2596 (411,
781) pg/ml, p,.0001, Two Way ANOVA).
doi:10.1371/journal.pone.0024398.g004
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vasculature of Pb-A infected naı ¨ve mice on day 6 (Figure 6A, and
6B, Naı ¨ve Challenged, solid black and hatched bars, 4.2+/22.1%
and 2.6+/20.7% of isolated cells, respectively). Microglia, NK
cells, and NKT cells were detected at low frequencies in these
experiments, and significant differences were not detected among
any of the sample groups (Figure 6B). The number of total cells
and specific cell types analyzed in each group are shown in
Figure 6C.
Surprisingly, CD8 T cells and macrophages were also detected
in the brains of mice immunized with 10
7 IrrPb on day 6 after
challenge, and their frequencies were not significantly different
from those observed in naı ¨ve mice during infection (Figure 6B, 10
7
IrrPb Challenged, solid black and hatched bars, 3.3+/20.2% and
2.0+/20.6% of isolated cells, respectively). In agreement with
previous reports in the Pb-A model, the brain-sequestered CD8 T
cells from infected naı ¨ve and immunized mice largely had a
CD44+ CD62L2 effector phenotype (Figure 6D, hatched bars),
and approximately 55% of these effector cells were also positive for
the early activation marker CD69+ (Figure 6E) consistent with
active, tissue invading cells. This indicated that immunization with
10
7 IrrPb protected mice from ECM after a virulent Pb-A
challenge without significantly reducing the infiltration of CD 8 T
cells into the brain vasculature.
Discussion
Some of the earliest malaria vaccine studies in experimental
models were based on the use of irradiation-attenuated whole
malaria parasites [24]. However, due to the perceived difficulties
related to their safety and large scale production, the whole
parasite approach was not considered to be a practical vaccine
strategy. In recent years, the limited success of sub-unit based
vaccines in clinical studies has reignited the interest in whole
parasite based malaria vaccines [11]. Notwithstanding their
potential value as candidate vaccines, studies with radiation-
attenuated parasites offer an excellent opportunity to explore host
pathogenesis and to examine the immune mechanisms induced by
protective vaccines against malaria.
In the current study, a single, non-adjuvanted immunization
with 10
7 irradiated blood-stage parasites protected CD1 mice from
parasitemia and severe disease, while up to two immunizations
with 10
3 irradiated parasites were not protective. This anti-parasite
immunity is consistent with previous studies of irradiated blood-
stage malaria parasites that showed protection from parasitemia
and severe malaria anemia in different model systems
[12,13,24,25,26]. The protection in the previous studies was
achieved without adjuvants, and it also required the intravenous
delivery of large numbers of blood-stage parasites.
To our knowledge, the current study is the first to also
demonstrate the effectiveness of irradiated blood-stage parasites
for protection against ECM, the most pathogenic consequence of
malaria infection. A single immunization with 10
7 irradiated
parasites protected against ECM, while two immunizations of 10
3
irradiated parasites did not protect. However, in contrast to
immunized CD1 mice, the immunized C57BL/6 mice that had
acquired anti-disease immunity against ECM did not acquire anti-
parasite immunity. Similar observations have been noted in other
experimental studies [23,27], suggesting that anti-disease immu-
nity and anti-parasite immunity act through distinct mechanisms.
This notion is further supported by the observations of distinct
immune mechanisms that confer immunity against severe malaria
and parasitemia in adults living in endemic areas [28,29].
The mechanism of protection in this study is not known, and
thus it is not clear what relative roles humoral and cellular
responses may have played for this protection. The protective
immunization against ECM in this study was associated with a
parasite-specific antibody response that increased following a boost
during a challenge infection. However, whether these antibodies
played any role against protection from ECM (C57Bl/6 mice) or
parasitemia (CD1 mice) is not clear. In previous studies, antibody
responses have been shown to be important to some whole
parasite vaccines [14,16], and it has been proposed that part of
their protective effects may come from an increased clearance of
opsonized parasites [30]. In the current study, the immunized
ECM-protected mice did not have significantly lower blood
parasitemia levels compared to non-protected mice, suggesting
that bulk parasite clearance is unlikely to fully explain protection.
However, the spleen sizes of protected mice increased 2-fold
during a virulent infection, and since this can be indicative of
increased parasite clearance and/or immune cell recruitment,
further experiments will be necessary to address this question in
detail. The ECM-protective immunization was also associated
with a reduced parasite-specific IFN-c response in the spleen
during a virulent infection. In mice that have a Th1 bias such as
C57BL/6, splenic IFN-c production during a blood-stage Pb-A
infection is thought to promote inflammatory responses that
contribute to ECM pathology [31]. In contrast, the non-protective
immunization in this study did not stimulate anti-parasite
antibodies and it only modestly reduced parasite-specific IFN-c
expression during an infection, indicating that it was less effective
at stimulating both antibody and cellular responses.
While elevated levels of splenic IFN-c during the fulminant
phase of Pb-A infection in mice are associated with susceptibility to
ECM, a very early IFN-c response in the spleen during infection
has been associated with resistance to ECM [32]. In a previous
study, it was proposed that CD 8+ T cells were a source of the
early splenic IFN-c responses during Pb-A infection, and the
authors provided evidence that NK cells, NKT cells, and cd T
cells did not significantly contribute to this IFN-c signal. In the
current study, the unchallenged, IrrPb immunized mice produced
detectable levels of splenic IFN-c when stimulated in vitro with Pb-
A antigen. While the source of this splenic IFN-c produced upon
immunization with IrrPb was not studied, we cannot discount the
possibility that antigenically primed CD 4+ T cells or some other
Figure 5. Spleen weights of mice immunized with IrrPb
increase during a virulent infection. C57BL/6 mice were immu-
nized once with 10
7 IrrPb, challenged with virulent parasites, and then
spleens were harvested on day 6 after challenge. Spleens from
immunized mice after challenge were an average 0.17 grams (0.09,
0.24) larger than the spleens from naı ¨ve mice after challenge (two-sided
p,.001, Two Way ANOVA, Bonferroni post test). Results (n=8 mice in
each group) are pooled from two independent experiments.
doi:10.1371/journal.pone.0024398.g005
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immunological feedback mechanism, since ECM-protected IrrPb
immunized mice had lower splenic IFN-c levels after Pb-A
challenge (Figure 5).
Recently, it has been proposed that immunization with
subpatent doses of viable blood-stage parasites that have been
genetically attenuated or curtailed by drug cure can provide
protection from a virulent challenge [16,18,33]. These are
intriguing findings, and may in part be linked to the degree to
which the attenuated parasites are able to replicate and persist to
stimulate the immune system without causing severe disease
symptoms. In the current study, even the largest inoculums of
irradiated parasites fell below the limit of blood-smear detection
within a few days, suggesting that these parasites were capable of
little or no replication. This level of attenuation was necessary
because it appeared that replication competent blood-stage Pb-A
Figure 6. Flow cytometry analysis of cell subtypes in brains of mice immunized with 10
7 IrrPb. Brain samples were processed on day 6
after virulent challenge and were pooled from all 4 mice in each group. Results are combined from two independent experiments. A) Representative
cell plots from naı ¨ve mouse brain samples during a virulent infection. Gates for macrophages (CD45+, CD11b+), microglia (CD45int, CD11b+), and
CD8 T cells (CD45+, CD3+, CD8+) are indicated. B) Graph of brain sequestered cell frequencies. Naı ¨ve mice had increased frequencies of brain-
sequestered CD8 T cells and macrophages during a virulent challenge (Naı ¨ve Challenged, black and hatched bars). Immunized challenged mice
displayed frequencies of brain-sequestered CD8 T cells and macrophages that were similar to frequencies observed in naı ¨ve mice during a challenge
(10
7 IrrPb Challenged, black and hatched bars). The mean difference in brain-sequestered CD8 T cells from 10
7 IrrPb challenged vs. naı ¨ve challenged
mice was 2.9 (22.8, 1.0)%, p=.12, Two Way ANOVA. C) Graph of the number of cells analyzed for each group. The absolute numbers of total cells
and CD8 T cells analyzed were not significantly different between the 10
7 IrrPb immunized and naı ¨ve groups, p..5, Two Way ANOVA. D) Brain-
sequestered CD8 T cells from both immunized and naı ¨ve mice largely had a CD44+ CD62L2 effector phenotype (hatched bars), and E) approximately
55% of these effector cells were also CD69+ in both Naı ¨ve mice and 10
7 IrrPb immunized mice after challenge.
doi:10.1371/journal.pone.0024398.g006
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disease. In another study, genetically attenuated, blood-stage Pb-A
parasites that retained an ability to replicate carried a very high
risk of severe disease themselves, although mice that survived the
initial vaccination developed robust immunity against both
parasites and disease during subsequent challenge infections
[14]. In the current study, low numbers of the non-replicating
parasites failed to induce anti-parasite or anti-disease immunity.
Although immunization with a high dose of irradiated Pb-A
protected mice against ECM in this study, the protected mice still
accumulated CD8 T cells in their brain vasculature similar to
ECM-susceptible mice. Previous studies have shown that brain
sequestered CD8 T cells are necessary but not sufficient for ECM
in the Pb-A model [34,35,36,37]. Similar to this study, perforin-
deficient mice that were resistant to ECM still accumulated
activated effector CD8 T cells (CD44+, CD62L2, CD69+)i n
their brains [35]. Further experimentation will be needed to
explore the mechanism of ECM resistance induced by irradiated
blood stage parasites.
In summary, inline with our results in the P. berghei model, it is
possible that a single inoculation with a high dose of replication-
deficient P. falciparum parasites might protect children in endemic
areas from parasite burden and/or cerebral malaria. In either
scenario, such a vaccine might lower the prospect of death from
severe malaria during their vulnerable early years and thus provide
them with the opportunity to develop clinical immunity after
continued parasite exposure.
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